Maria, APA; Ruth, UP; Angel, CHM; Patricia, AA; Barbara, CD; Monica, FM

[Ana Maria, Alanon Pardo; Miguel Angel, Calleja Hernandez; Diez Barbara, Candela; Martin Monica, Ferrit] Hosp Univ Virgen de las Nieves, Hosp Pharm, Pharm Serv, Granada, Spain; [Perez Ruth, Ubago] AETSA, Hosp Pharm, Seville, Spain; [Arroyo Patricia, Araque] Hosp La Mancha, Ctr Alcazar de San Juan, Pharm Serv, Hosp Pharm, Ciudad Real, Spain

Objective: To analyze the degree of adaptation in the chemotherapy prescriptions for breast cancer therapy to the Integrated Care Process (ICP) and the Spanish Society of Gynecology and Obstetrics (SEGO) protocols; identify the causes of no-adaptation; and assess the survival rate according to the adaptation. Method: A retrospective observational study was conducted on patients who were diagnosed with breast cancer in 2006 and treated with chemotherapy since that year. A follow-up was performed until December 2010. Results: 131 patients who received a total of 189 treatments were included. The overall adaptation to the ICP was 27% and 21.7% to the SEGO. The most frequent causes of no adaptation were related to the indication and the used regimen. The five year survival rate in the groups of no-adaptation to both protocols was higher than the calculated for the groups of yes-adaptation, with statistically significant differences in both cases. Conclusions: The degree of adaptation to both protocols is low and does not seem to be directly related to an improvement in the survival rate.